The antipsychotic agent quetiapine is increasingly not used as such: dispensed prescriptions in Norway 2004–2015
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Purpose The antipsychotic agent quetiapine was introduced in Norway in 2003. We have assessed changes in dispensed prescriptions, including dosing, of quetiapine in Norway from 2004 to 2015.Methods Data on the sales of antipsychotics and antidepressants were drawn from the Norwegian Prescription Database. A total of 47,474 outpatients filled 195,622 prescriptions of quetiapine. Reimbursement codes, use of antipsychotics or antidepressants 12 months prior to the first prescription of quetiapine and estimated mean volume used measured as defined daily doses (DDDs) per day were used as proxies for diagnoses. We conducted a regression analysis with DDD per day as a function of possible explanatory variables.Results The number of users filling at least two prescriptions of quetiapine per year increased from 584 in 2004 to 8506 in 2015 and the mean dose declined from 1.58 DDD per day (SD 8.00) to 0.48 DDD per day (SD 2.27). The latter is much lower than recommended for treatment of psychoses. In 2015, 60.1% of the 8506 quetiapine users did not seek reimbursement for the treatment of a major psychiatric disorder and only 2.6% of the patients were prescribed 1 DDD or more per day and reimbursed in accordance with the drug's primary indication, psychosis. A reported diagnosis of psychosis was not associated with higher quetiapine doses.Conclusions In 2015, the pattern of quetiapine dispensing in Norway most likely reflects predominant off-label use. This is unsettling considering poorly documented effects in non-psychotic disorders, profound side effects, significant toxicity and growing concern regarding abuse.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Out of 92 participating clients, some 30% reported a lifetime history of non-medical use of olanzapine, with 9 people (10%) having reported daily dosages of 30 mg or higher and 3 people (3%) typically ingesting 100 mg.”
Citations
Cites
Tiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354
International Consensus Study of Antipsychotic Dosing
Gardner, D. M., Murphy, A. L., O'Donnell, H., Centorrino, F., & Baldessarini, R. J. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09060802 · Cited by 1,301
Calabrese, J. R., Keck, P. E., Macfadden, W., Minkwitz, M., Ketter, T. A., Weisler, R. H., Cutler, A. J., McCoy, R., Wilson, E., Mullen, J., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.7.1351 · Cited by 883
Wilson, S., Nutt, D., Alford, C., Argyropoulos, S., Baldwin, D., Bateson, A., Britton, T., Crowe, C., Dijk, D.-J., Espie, C., et al. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881110379307 · Cited by 634
Thase, M. E., Macfadden, W., Weisler, R. H., Chang, W., Paulsson, B., Khan, A., & Calabrese, J. R. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000248603.76231.b7 · Cited by 559
Association of Off-label Drug Use and Adverse Drug Events in an Adult Population
Eguale, T., Buckeridge, D. L., Verma, A., Winslade, N. E., Benedetti, A., Hanley, J. A., & Tamblyn, R. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.6058 · Cited by 262
Antipsychotic prescribing trends: a review of pharmaco‐epidemiological studies
Verdoux, H., Tournier, M., & Bégaud, B. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01425.x · Cited by 249
Carton, L., Cottencin, O., Lapeyre-Mestre, M., Geoffroy, P., Favre, J., Simon, N., Bordet, R., & Rolland, B. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150619092903 · Cited by 204
Prescribing of antipsychotics in UK primary care: a cohort study
Marston, L., Nazareth, I., Petersen, I., Walters, K., & Osborn, D. P. J. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-006135 · Cited by 193
Quetiapine for insomnia: A review of the literature
Anderson, S. L., & Vande Griend, J. P. (2014) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp130221 · Cited by 127
Atypical antipsychotics for insomnia: a systematic review
Thompson, W., Quay, T. A. W., Rojas‐Fernandez, C. H., Farrell, B. J., & Bjerre, L. M. (2016) · Sleep Medicine · doi:10.1016/j.sleep.2016.04.003 · Cited by 107
Acute Quetiapine Overdose in Adults: A 5-Year Retrospective Case Series
Ngo, A., Ciranni, M. A., & Olson, K. R. (2008) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2008.03.016 · Cited by 93
Pringsheim, T., & Gardner, D. M. (2014) · CMAJ Open · doi:10.9778/cmajo.20140009 · Cited by 93
Brett, J. (2015) · Australian Prescriber · doi:10.18773/austprescr.2015.032 · Cited by 54
Misuse of atypical antipsychotics in conjunction with alcohol and other drugs of abuse
Malekshahi, T., Tioleco, N., Ahmed, N., Campbell, A. N. C., & Haller, D. (2015) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2014.07.006 · Cited by 53
Soeiro‐de‐Souza, M. G., Dias, V. V., Missio, G., Balanzá‐Martínez, V., Valiengo, L. D. C. L., Carvalho, A. F., & Moreno, R. A. (2015) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2015.2213 · Cited by 40
Biederman, J., Mick, E., Faraone, S., Hammerness, P., Surman, C., Harpold, T., Dougherty, M., Aleardi, M., & Spencer, T. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000204139.20417.8a · Cited by 37
Off-label use of atypical antipsychotic medications in Canterbury, New Zealand.
Monasterio, E., & McKean, A. (2011) · PubMed · Cited by 29
Misuse and Associated Harms of Quetiapine and Other Atypical Antipsychotics
Montebello, M. E., & Brett, J. (2015) · Current topics in behavioral neurosciences · doi:10.1007/7854_2015_424 · Cited by 28
Misuse and abuse of quetiapine
Piróg-Balcerzak, A., Habrat, B., & Mierzejewski, P. (2015) · Psychiatria Polska · doi:10.12740/pp/32923 · Cited by 21
Morrens, M., Destoop, M., Cleymans, S., SPEK, S. V. D., & Dom, G. (2015) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000085 · Cited by 17
Reddel, S., Bruno, R., Burns, L., Kirwan, A., Lokuge, K., & Dietze, P. (2013) · Addiction · doi:10.1111/add.12395 · Cited by 10
Research works printed but not linked: 3
- Furu K, Strøm H, Rønning M et al (2005) The Norwegian Prescription Database (NorPD): new register for pharmacoepidemiological research covering a whole nation. Pharmacoepidemiol Drug Saf 14(Suppl. 2):S48
- WHO Collaborating Centre for Drug Statistics Methodology (2016) ATC/DDD index 2016. WHO, Oslo
- Maglione M, Ruelaz Maher A, Hu J et al (2011) Off-label use of atypical antipsychotics: an update. Comparative effectiveness review no. 43. AHRQ publication no. 11-EHC078-EF. Agency for healthcare research and quality, Rockville
Cited by
Effects of age and gender on the serum levels of clozapine, olanzapine, risperidone, and quetiapine
Castberg, I., Westin, A. A., Skogvoll, E., & Spigset, O. (2017) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12794 · Cited by 107
Trends in utilization and dosing of antipsychotic drugs in Scandinavia: Comparison of 2006 and 2016
Højlund, M., Pottegård, A., Johnsen, E., Kroken, R. A., Reutfors, J., Munk‐Jørgensen, P., & Correll, C. U. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13945 · Cited by 72
Højlund, M., Andersen, K., Ernst, M. T., Correll, C. U., & Hallas, J. (2022) · World Psychiatry · doi:10.1002/wps.21010 · Cited by 68
Højlund, M., Andersen, J. H., Andersen, K., Correll, C. U., & Hallas, J. (2021) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796021000159 · Cited by 45
Chiappini, S., & Schifano, F. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000814 · Cited by 44
Metadata
- Authors
- Gjerden, P., Bramness, J. G., Tvete, I. F., & Slørdal, L.
- Affiliations
- Telemark Hospital (NO)
- Innlandet Hospital Trust (NO)
- Norwegian Computing Center (NO)
- Norwegian University of Science and Technology (NO)
- Corresponding author
- Gjerden, Pål
- Venue
- European Journal of Clinical Pharmacology
- Published
- 2017-06-16
- Volume
- 73
- Issue
- 9
- Pages
- 1173-1179
- ISSN
- 0031-6970 (ISSN-L)
- 1432-1041
- OpenAlex
- W2625982650
- Cited by
- 48
- References
- 22
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 3 · 2023: 3 · 2022: 5 · 2021: 12 · 2020: 4 · 2019: 5 · 2018: 6 · 2017: 2
- FWCI
- 3.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Clinical Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- The Johanne and Einar Eilertsen's research foundation in the memory of their son Johan Eilertsen
- The Thora and Sverre Lofthus foundation
- The Institute of Laboratory Medicine, Children's and Women's Health, The Norwegian University of Science and Technology
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- quetiapine, off-label drug use, antipsychotic prescribing, psychosis, defined daily doses, prescribing patterns, antidepressant use, reimbursement codes, drug abuse, Norway
- MeSH terms
- Quetiapine Fumarate, Adolescent, Adult, Aged, Antidepressive Agents, Child, Drug Utilization, Female, Humans, Male, Norway, Antipsychotic Agents, Databases, Factual, Young Adult, Off-Label Use
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.